XML 68 R23.htm IDEA: XBRL DOCUMENT v2.4.0.6
Fair Value Measurements (Tables)
3 Months Ended
Mar. 31, 2013
Fair Value Disclosures [Abstract]  
Carrying amounts and estimated fair values of other financial instruments
The following table presents the carrying amounts and estimated fair values of our other financial instruments at March 31, 2013 and December 31, 2012 (in thousands):
 
March 31, 2013
 
December 31, 2012
 
Carrying
Amount
 
Fair Value
 
Carrying
Amount 
 
Fair Value
Current assets:
 
 
 
 
 
 
 
Derivative instruments
$
85

 
$
85

 
$
—

 
$
—

 
$
85

 
$
85

 
$
—

 
$
—

Long-term assets:
 
 
 
 
 
 
 
Equity securities
$
2,539

 
$
2,539

 
$
1,746

 
$
1,746

Equity and cost method investments
14,427

 
N/A

 
15,195

 
N/A

 
$
16,966

 
 
 
$
16,941

 
 
Current liabilities:
 
 
 
 
 
 
 
Acquisition-related contingent consideration—short-term
$
1,194

 
$
1,194

 
$
6,195

 
$
6,195

Current portion of Term Loan A Facility Due 2018
69,375

 
69,375

 
131,250

 
131,250

3.25% AMS Convertible Notes due 2036
795

 
795

 
795

 
795

4.00% AMS Convertible Notes due 2041
111

 
111

 
111

 
111

Current portion of other long-term debt
1,687

 
1,687

 
1,842

 
1,842

Derivative instruments
191

 
191

 
602

 
602

Minimum Voltaren® Gel royalties due to Novartis—short-term
32,093

 
32,093

 
31,878

 
31,878

Other
1,000

 
1,000

 
1,000

 
1,000

 
$
106,446

 
$
106,446

 
$
173,673

 
$
173,673

Long-term liabilities:
 
 
 
 
 
 
 
Acquisition-related contingent consideration—long-term
$
2,770

 
$
2,770

 
$
2,729

 
$
2,729

1.75% Convertible Senior Subordinated Notes Due 2015, net
327,120

 
364,478

 
321,332

 
364,444

Term Loan A Facility Due 2018, less current portion
1,318,125

 
1,321,455

 
1,256,250

 
1,259,094

Term Loan B Facility Due 2018
60,550

 
60,992

 
160,550

 
162,260

7.00% Senior Notes Due 2019
500,000

 
535,938

 
500,000

 
536,563

7.00% Senior Notes Due 2020, net
396,973

 
427,500

 
396,899

 
429,000

7.25% Senior Notes Due 2022
400,000

 
429,000

 
400,000

 
431,500

Other long-term debt, less current portion
3,294

 
3,294

 
2,916

 
2,916

Minimum Voltaren® Gel royalties due to Novartis—long-term
6,615

 
6,615

 
13,846

 
13,846

Other
5,150

 
5,150

 
5,775

 
5,775

 
$
3,020,597

 
$
3,157,192

 
$
3,060,297

 
$
3,208,127

Financial assets and liabilities measured at fair value on recurring basis
The Company’s financial assets and liabilities measured at fair value on a recurring basis at March 31, 2013 and December 31, 2012 were as follows (in thousands):     
 
Fair Value Measurements at Reporting Date using  
March 31, 2013
Quoted Prices in
Active Markets
for Identical
Assets (Level 1)
 
Significant Other
Observable
Inputs (Level 2)  
 
Significant
Unobservable
Inputs (Level 3)
 
Total
Assets:
 
 
 
 
 
 
 
Equity securities
$
2,539

 
$
—

 
$
—

 
$
2,539

Derivative instruments
—

 
85

 
—

 
85

Total
$
2,539

 
$
85

 
$
—

 
$
2,624

Liabilities:
 
 
 
 
 
 
 
Derivative instruments
$
—

 
$
191

 
$
—

 
$
191

Acquisition-related contingent consideration—short-term
—

 
—

 
1,194

 
1,194

Acquisition-related contingent consideration—long-term
—

 
—

 
2,770

 
2,770

Total
$
—

 
$
191

 
$
3,964

 
$
4,155

 
 
Fair Value Measurements at Reporting Date using
December 31, 2012
Quoted Prices in
Active Markets
for Identical
Assets (Level 1) 
 
Significant Other
Observable
Inputs (Level 2)
 
Significant
Unobservable
Inputs (Level 3)
 
Total
Assets:
 
 
 
 
 
 
 
Equity securities
$
1,746

 
$
—

 
$
—

 
$
1,746

Total
$
1,746

 
$
—

 
$
—

 
$
1,746

Liabilities:
 
 
 
 
 
 
 
Derivative instruments
$
—

 
$
602

 
$
—

 
$
602

Acquisition-related contingent consideration—short-term
—

 
—

 
6,195

 
6,195

Acquisition-related contingent consideration—long-term
—

 
—

 
2,729

 
2,729

Total
$
—

 
$
602

 
$
8,924

 
$
9,526

Financial liabilities measured at fair value on recurring basis using significant unobservable inputs
The following table presents changes to the Company’s financial liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the three months ended March 31, 2013 (in thousands):
 
Acquisition-
related
Contingent
Consideration  
Liabilities:
 
January 1, 2013
$
(8,924
)
Amounts (acquired) sold / (issued) settled, net
5,000

Transfers in and/or (out) of Level 3
—

Changes in fair value recorded in earnings
(40
)
March 31, 2013
$
(3,964
)
The following table presents changes to the Company’s financial liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the three months ended March 31, 2012 (in thousands):
 
Acquisition-related
Contingent  Consideration
Liabilities:
 
January 1, 2012
$
(8,687
)
Amounts (acquired) sold / (issued) settled, net
—

Transfers in and/or (out) of Level 3
—

Changes in fair value recorded in earnings
127

March 31, 2012
$
(8,560
)
Summary of available-for-sale securities
The following is a summary of available-for-sale securities held by the Company at March 31, 2013 and December 31, 2012 (in thousands):
 
Available-for-sale  
 
Amortized
Cost  
 
Gross
Unrealized
Gains
 
Gross
Unrealized
(Losses) 
 
Fair Value  
March 31, 2013
 
 
 
 
 
 
 
Equity securities
$
1,766

 
$
773

 
$
—

 
$
2,539

Long-term available-for-sale securities
$
1,766

 
$
773

 
$
—

 
$
2,539

Total available-for-sale securities
$
1,766

 
$
773

 
$
—

 
$
2,539


 
Available-for-sale  
 
Amortized
Cost
 
Gross
Unrealized
Gains 
 
Gross
Unrealized
(Losses)  
 
Fair Value  
December 31, 2012
 
 
 
 
 
 
 
Equity securities
$
1,766

 
$
—

 
$
(20
)
 
$
1,746

Long-term available-for-sale securities
$
1,766

 
$
—

 
$
(20
)
 
$
1,746

Total available-for-sale securities
$
1,766

 
$
—

 
$
(20
)
 
$
1,746